Louise D. Johnson

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

María Romina Girotti, Filipa M. Lopes, Natasha Preece et al. · Cancer Cell · 2014 · 209 citations · Full text

Medicine, Cancer Biology, Oncology +17

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>In Vitro</i> and <i>In Vivo</i>

Jane Renshaw, Kathryn R. Taylor, Ryan T. Bishop et al. · Clinical Cancer Research · 2013 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface

Haoran Tang, Leo Leung, Grazia Saturno et al. · Nature Communications · 2017 · 87 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders

Benjamin R. Bellenie, Kwai-Ming J. Cheung, Ana Varela et al. · Journal of Medicinal Chemistry · 2020 · 73 citations · Full text

Medicine, Oncology, Pharmacology +11

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships

Leo Leung, Dan Niculescu‐Duvaz, Deborah A. Smithen et al. · Journal of Medicinal Chemistry · 2019 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15